BR112013016254A2 - agentes oprf/i e seu uso em pacientes hospitalizados e outros - Google Patents

agentes oprf/i e seu uso em pacientes hospitalizados e outros

Info

Publication number
BR112013016254A2
BR112013016254A2 BR112013016254A BR112013016254A BR112013016254A2 BR 112013016254 A2 BR112013016254 A2 BR 112013016254A2 BR 112013016254 A BR112013016254 A BR 112013016254A BR 112013016254 A BR112013016254 A BR 112013016254A BR 112013016254 A2 BR112013016254 A2 BR 112013016254A2
Authority
BR
Brazil
Prior art keywords
oprf
agents
hospitalized patients
hospitalized
patients
Prior art date
Application number
BR112013016254A
Other languages
English (en)
Portuguese (pt)
Inventor
Klade Christoph
Westritschnig Kerstin
Schlegl Robert
Original Assignee
Intercell Austria Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria Ag filed Critical Intercell Austria Ag
Publication of BR112013016254A2 publication Critical patent/BR112013016254A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013016254A 2010-12-23 2011-03-18 agentes oprf/i e seu uso em pacientes hospitalizados e outros BR112013016254A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (1)

Publication Number Publication Date
BR112013016254A2 true BR112013016254A2 (pt) 2017-07-11

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013016254A BR112013016254A2 (pt) 2010-12-23 2011-03-18 agentes oprf/i e seu uso em pacientes hospitalizados e outros

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201706671WA (en) 2012-11-30 2017-09-28 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EA201790489A1 (ru) * 2014-08-29 2017-08-31 Сорренто Терапьютикс, Инк. ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI
US10344078B2 (en) 2015-05-01 2019-07-09 Inhibrx, Inc. Type III secretion system targeting molecules
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
SG10201912410TA (en) 2015-07-16 2020-02-27 Inhibrx Inc Multivalent and multispecific dr5-binding fusion proteins
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
JP2005501889A (ja) * 2001-09-03 2005-01-20 アンビクス パテンツ−ライセンシーズ アーゲー マクロライド系抗生物質を用いる緑膿菌感染症の治療法
ES2431318T3 (es) * 2001-11-13 2013-11-26 Id Biomedical Corporation Polipéptidos de Pseudomonas aeruginosa
BRPI0406800B8 (pt) * 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
BRPI0517200A (pt) * 2004-12-17 2008-09-30 Venus Remedies Ltd combinações de antibióticos, processos de preparação de uma combinação de antibióticos e método de tratamento
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
SG10201706671WA (en) * 2012-11-30 2017-09-28 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Also Published As

Publication number Publication date
WO2012084272A1 (en) 2012-06-28
CN103270047A (zh) 2013-08-28
JP2014504297A (ja) 2014-02-20
AU2011348396A2 (en) 2013-07-11
MX2013007146A (es) 2013-11-01
CA2822684A1 (en) 2012-06-28
KR20130133212A (ko) 2013-12-06
JP5893640B2 (ja) 2016-03-23
ZA201304235B (en) 2014-09-25
AU2011348396A1 (en) 2013-07-04
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
EP2655402A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
CY2021021I2 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
BR112013016254A2 (pt) agentes oprf/i e seu uso em pacientes hospitalizados e outros
SMT201400146B (it) Morfolino pirimidine e loro uso in terapia
BR112013033316A2 (pt) antagonista de trpm8 e seu uso em tratamentos
SI2569009T1 (sl) Himere OSPA in njihova uporaba v cepivih
BRPI1010533A2 (pt) tetrahidroazolopirazinas sulfoniladas e seu uso como medicamentos
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BR112013011520A2 (pt) pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
PL2648726T3 (pl) Policykliczny antagonista lpa1 i jego zastosowania
DK2635607T3 (da) Stabilt heterodimert antistofdesign med mutationer i fc-domænet
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
BR112012031194A2 (pt) derivados de cisteamina e seu uso no tratamento de ehna
BR112015015385A2 (pt) núcleo absorvente apresentando deformação controlada em uso e artigo absorvente compreendendo o referido núcleo
BR112013007506A2 (pt) piridinonas/pirazinonas - métodos de criação e de uso
BR112013010988A2 (pt) composição fluída e uso
BR112013012185A2 (pt) unidade cosmética com reservatório comprimível e seu uso
BR112013015378A2 (pt) misturador dinâmico e seu uso
BR112012029844A2 (pt) uso de metamorfina em combinação com um ativador de glucoquinase e combinações compreendendo metamorfina com um ativador de glucoquinase
FR2963612B1 (fr) Element en treillis et grue
BR112013022285A2 (pt) proteína de fusão de fgfr-fc e o seu uso
HRP20171280T1 (hr) Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji
BR302012001336S1 (pt) Configuração aplicada em instrumento médico
CO6781486A2 (es) Compuestos y su uso
BR112013008898A2 (pt) benzamidas substituídas e seus usos
BRPI0920502A2 (pt) compostos cicloundecadepsipeptídeos e seu uso como medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25B Requested transfer of rights rejected

Owner name: INTERCELL AUSTRIA AG (AT)

B25D Requested change of name of applicant approved

Owner name: VALNEVA AUSTRIA GMBH (AT)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]